AdderaCare is a corporate group focused on acquiring companies in the accessibility and home care sector with the aim to improve the quality of life for people with functional limitations. The Group currently consists of five product companies including Trident, Komikapp, Amajo, Erimed and Huka whose products include ramps, stairs, lifts, bathroom equipment, prothesis, orthoses, orthopaedic shoes, sensory products and more. AdderaCare’s customers include municipalities, county councils as well as private individuals.
For more information, see www.adderacare.com
Arcoma was founded in 1990 and is a Swedish provider of complete radiology solutions used in key clinical application areas within radiology. The product portfolio includes a combination of detectors, generators, software and positioning systems to create an optimal configuration for diagnosis. Arcoma’s solutions aim to shorten the lead time between diagnosis and treatment of patients through efficient, reliable and excellent diagnostic results. The products are sold worldwide with the mission to improve patient care, as well as the work environment for the user.
For more information, see www.arcoma.se
Calliditas Therapeutics is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company was founded in 2004 with the goal of developing and commercializing Nefecon, which is Calliditas’ current lead product candidate. Nefecon is a proprietary, novel oral formulation of budesonide used for the treatment of the autoimmune renal disease IgA nephropathy (IgAN). The product is currently in phase 3 of its clinical development.
For more information, see www.calliditas.se
Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.
The Company’s lead candidate Emcitate is under development for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment.
For more information, see www.egetis.com
FluoGuide was founded in 2018 after decades of ground-breaking research on imaging, cancer and uPAR which is one of the well-established markers of cancer aggressiveness. The company develops surgical solutions that help reduce suffering for patients and increase the chances of cure, as well as reducing costs for the health care system. The company’s leading product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue when injected to patients. This enables surgeons to locate and remove the cancer more efficiently
For more information, see www.fluoguide.com
InDex Pharma is a Stockholm-based pharmaceutical company founded in 2000. The company has a platform for developing therapies against immunological diseases with a high unmet medical need. InDex’s lead product, cobitolimod, is in late clinical development for the treatment of moderate to severe refractory, active ulcerative colitis, a debilitating, chronic inflammation of the large intestine. Cobitolimod has been successful in a phase 2b trial, demonstrating a combination of efficacy and a favourable safety profile. Preparations for registration studies are currently underway.
For more information, see www.indexpharma.com
Initiator Pharma is a pharmaceutical company, that has developed two proprietary products for treatment of erectile dysfunction. Its’ products have reached Phase II clinical trials, IPED2015 and IP2018 for erectile dysfunction. Both compounds constitute new treatments for the indication of erectile dysfunction of either organic or psychogenic origin, respectively – the inability of a man to achieve and maintain an erection and thus be able to complete sexual intercourse. Initiator Pharma’s new treatment method with IPED2015 is intended to treat many patients with erectile dysfunction who are resistant to current treatment methods.
For more information, see www.initiatorpharma.com
MedCap is a decentralised investment company focused on relationship-based investments in small and mid-sized non-listed medtech and speciality pharma companies. The Company makes majority investments in Central and Northern European companies with international potential and targets an investment size of SEK 50-500m (EUR 5-50m). MedCap has an active ownership agenda and seeks to develop its portfolio companies by contributing capital, expertise, experience and relevant industry networks. The Company has a flexibile investment horizon and is targeting 5-10 core investments.
For more information, see www.medcap.se
Medivir is a pharmaceutical company investing in the clinical development of innovative cancer drugs. The company was founded in 1988 and has since then developed two pharmaceutical products, Xerclear and Olysio, all the way from idea to market launch, and has also ventured into more than twenty partnership agreements. The company’s current project portfolio comprises four drug development projects in clinical development stage. Medivir is mainly focused on the in-house development of MIV-818 for liver cancer. For the other three projects, remetinostat, birinapant and MIV-711, the company is looking for partners for further development of the projects.
For more information, see www.medivir.se
OncoZenge is a pharmaceutical company founded in 2020 originating from a collaboration between Moberg Pharma and clinicians from Hvidovre in Denmark. The company develops products for cancer supportive care and is currently focused on preparing a phase 3 trial for the lead asset, BupiZenge, which is intended for treatment of pain in the oral cavity. The first indication of BupiZenge is treatment for pain caused by oral mucositis, but it also has potential for treatment of other painful oral conditions. Oral mucositis is a side effect of chemotherapy and radiotherapy and causes inflammation and ulceration of the mouth and pharynx.
For more information, see www.oncozenge.se
OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give back patients the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.
For more information, see www.ossdsign.com
Sedana Medical was founded in 2005 and is a medtech company active in the field of inhaled sedation with the ambition to develop a new global standard for therapy in intensive care. The Company has developed a delivery system, called AnaConDa, for the administration of isoflurane or sevoflurane to mechanically ventilated patients. Sedana Medical is now conducting a clinical phase III study aimed at getting its drug candidate IsoConDa (isoflurane) approved for inhaled sedation in Europe (through AnaConDa).
For more information, see www.sedanamedical.se
Stille was founded in 1841 and is a leading provider of surgical equipment and solutions that are used in modern surgical procedures. The Company is focused on the two market segments cardiovascular and plastic surgery where it delivers surgical instruments such as scissors, forceps, retractors and advanced operating tables. Stille’s clients primarily include hospitals, clinics and outpatient surgery units in North America and Europe.)
For more information, see https://www.stille.se